19 May 2022 - - US-based biotechnology company Autobahn Therapeutics has posted new preclinical data supporting the potential of its novel CNS-directed thyromimetic program to induce remyelination in models where loss of myelin is a key driver of disease, the company said.

The results highlight the utility of Autobahn's lead program, ABX-002, in demyelinating diseases. ABX-002 is an amide prodrug which readily crosses the blood-brain barrier and is then cleaved by fatty acid amide hydrolase resulting in enhanced delivery of the active metabolite to the brain.

The data will be presented by collaborators from the University of Wisconsin and the University of Colorado Anschutz Medical Campus at the Myelin Gordon Research Conference and the Cold Spring Harbor Lab Glia Meeting, respectively.

Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders.

Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules.

The company's pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed for the treatment of several CNS diseases, including treatment resistant depression, multiple sclerosis and adrenomyeloneuropathy, a rare genetic disorder.

Autobahn Therapeutics is based in San Diego.